Venturing into ophthalmic space

Venturing into ophthalmic space

Company Type Date Raised Description
Alacrity Biosciences Debt 3/5/07 $8.5 Developing compounds to treat ocular surface diseases, glaucoma and retinal disease. Lead compound is ALTY-0501, a topical formulation of doxycycline that has completed a Phase II trial.
Alimera Sciences Series C 3/18/08 $30.0 Focused on diseases that affect the back of the eye (retina). Lead compound is Iluvien,

Read the full 761 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE